GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tengion Inc (GREY:TNGNQ) » Definitions » Return-on-Tangible-Asset

Tengion (Tengion) Return-on-Tangible-Asset : -616.41% (As of Sep. 2014)


View and export this data going back to 2010. Start your Free Trial

What is Tengion Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Tengion's annualized Net Income for the quarter that ended in Sep. 2014 was $-73.41 Mil. Tengion's average total tangible assets for the quarter that ended in Sep. 2014 was $11.91 Mil. Therefore, Tengion's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2014 was -616.41%.

The historical rank and industry rank for Tengion's Return-on-Tangible-Asset or its related term are showing as below:

TNGNQ's Return-on-Tangible-Asset is not ranked *
in the Biotechnology industry.
Industry Median: -40.335
* Ranked among companies with meaningful Return-on-Tangible-Asset only.

Tengion Return-on-Tangible-Asset Historical Data

The historical data trend for Tengion's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tengion Return-on-Tangible-Asset Chart

Tengion Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Return-on-Tangible-Asset
Get a 7-Day Free Trial -54.50 -83.41 -90.85 -111.92 -99.20

Tengion Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -81.95 83.87 -608.15 -425.90 -616.41

Competitive Comparison of Tengion's Return-on-Tangible-Asset

For the Biotechnology subindustry, Tengion's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tengion's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tengion's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Tengion's Return-on-Tangible-Asset falls into.



Tengion Return-on-Tangible-Asset Calculation

Tengion's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2013 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2013 )  (A: Dec. 2012 )(A: Dec. 2013 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2013 )  (A: Dec. 2012 )(A: Dec. 2013 )
=-18.927/( (12.435+25.724)/ 2 )
=-18.927/19.0795
=-99.20 %

Tengion's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2014 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Sep. 2014 )  (Q: Jun. 2014 )(Q: Sep. 2014 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Sep. 2014 )  (Q: Jun. 2014 )(Q: Sep. 2014 )
=-73.408/( (14.197+9.621)/ 2 )
=-73.408/11.909
=-616.41 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2014) net income data.


Tengion  (GREY:TNGNQ) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Tengion Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Tengion's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Tengion (Tengion) Business Description

Traded in Other Exchanges
N/A
Address
3929 Westpoint Boulevard, Suite G, Winston-Salem, NC, USA, 27103
Tengion Inc is a regenerative medicine company. The company is engaged in discovering, manufacturing and commercializing neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace damaged tissue or organ. Its product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. The company's solution Neo-Kidney Augment is based on its proprietary technology, which uses tubular epithelial cells, procured by a cortical biopsy of the patient's kidney, to create an injectable product candidate that can catalyze the regeneration of functional kidney tissue.
Executives
John L Miclot director, officer: President and CEO 5005 OLD ORCHARD LANE, GIBSONIA PA 15044
Lorin Randall director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
A Brian Davis officer: Chf. Fin. Offr, VP Fin. C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Medtronic Inc 10 percent owner 710 MEDTRONIC PKWY, MINNEAPOLIS MN 55432
Johan Christenson 10 percent owner C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51
Staffan Lindstrand 10 percent owner C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51
Richard Kuntz director MEDTRONIC, INC., 710 MEDTRONIC PWKY MS LC 310, MINNEAPOLIS MN 55432
Diane Jorkasky director 60 MANOR AVENUE, WELLESLEY MA 02482
Mark Stejbach officer: VP and Chief Commercial Offcr C/O TENGION, INC., 2900 POTSHOP LANE, SUITE 100, EAST NORRITON PA 19403
Steven Nichtberger director, officer: President and CEO C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
Johnson & Johnson 10 percent owner ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ 08933
Johnson & Johnson Innovation - Jjdc, Inc. 10 percent owner 410 GEORGE STREET, NEW BRUNSWICK NJ 08901
Oak Investment Partners Xi L P 10 percent owner 901 MAIN AVENUE, SUITE 600, NORWALK CT 06851

Tengion (Tengion) Headlines

From GuruFocus

Tengion Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 05-20-2010